Brigatinib is a medication being studied for its effectiveness in treating certain types of cancer in children and young adults. It is used in patients who have a specific genetic marker known as ALK+ (anaplastic lymphoma kinase positive). This includes conditions like Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), and other solid tumors. The study aims to find the best dose of brigatinib for these patients and to understand how the body processes the medication. Additionally, the study is looking at how well brigatinib works in shrinking tumors and improving patient outcomes over a period of two years.

Anaplastic Large Cell Lymphoma (ALCL) – This is a type of non-Hodgkin lymphoma characterized by the presence of large, abnormal lymphocytes. It often begins in the lymph nodes but can also affect other parts of the body. The disease can progress by spreading to other lymph nodes and organs. Symptoms may include swollen lymph nodes, fever, and weight loss. ALCL is associated with a specific genetic mutation involving the ALK gene. The progression can vary, with some cases being more aggressive than others.

Inflammatory Myofibroblastic Tumors (IMT) – These are rare tumors that can occur in various parts of the body, including the lungs, abdomen, and pelvis. They are characterized by the proliferation of myofibroblastic cells and inflammatory cells. IMTs can grow slowly and may cause symptoms depending on their location, such as pain or swelling. The tumors are often associated with genetic changes involving the ALK gene. While they are generally considered benign, they can sometimes behave aggressively. The progression of IMT can vary, with some tumors remaining stable for long periods.

Other Solid Tumors – This term refers to a diverse group of cancers that form solid masses in various tissues and organs. These tumors can arise in any part of the body, such as the lungs, liver, or bones. The progression of solid tumors depends on the type and location, with some growing slowly and others more rapidly. Symptoms vary widely based on the tumor’s location and size, potentially causing pain, swelling, or organ dysfunction. Genetic mutations, including those involving the ALK gene, can play a role in the development of these tumors. The behavior and progression of solid tumors can be unpredictable, requiring careful monitoring.